890841-51-7Relevant academic research and scientific papers
Chroman and tetrahydroquinoline ureas as potent TRPV1 antagonists
Schmidt, Robert G.,Bayburt, Erol K.,Latshaw, Steven P.,Koenig, John R.,Daanen, Jerome F.,McDonald, Heath A.,Bianchi, Bruce R.,Zhong, Chengmin,Joshi, Shailen,Honore, Prisca,Marsh, Kennan C.,Lee, Chih-Hung,Faltynek, Connie R.,Gomtsyan, Arthur
, p. 1338 - 1341 (2011)
Novel chroman and tetrahydroquinoline ureas were synthesized and evaluated for their activity as TRPV1 antagonists. It was found that aryl substituents on the 7- or 8-position of both bicyclic scaffolds imparted the best in vitro potency at TRPV1. The most potent chroman ureas were assessed in chronic and acute pain models, and compounds with the ability to cross the blood-brain barrier were shown to be highly efficacious. The tetrahydroquinoline ureas were found to be potent CYP3A4 inhibitors, but replacement of bulky substituents at the nitrogen atom of the tetrahydroisoquinoline moiety with small groups such as methyl can minimize the inhibition.
Cyclodextrin-complexed RAFT agents for the ambient temperature aqueous living/controlled radical polymerization of acrylamido monomers
Schmidt, Bernhard V. K. J.,Hetzer, Martin,Ritter, Helmut,Barner-Kowollik, Christopher
experimental part, p. 7220 - 7232 (2012/04/10)
The first aqueous reversible addition-fragmentation transfer (RAFT) polymerization of N,N-dimethylacrylamide (DMAAm), N,N-diethylacrylamide (DEAAm), and N-isopropylacrylamide (NIPAAm) utilizing host/guest complexes of cyclodextrin and hydrophobic chain transfer agents (CTAs) at 25 °C is described. Three novel guest-functionalized CTAs, namely 4-(tert-butyl)phenyl 2-(((ethylthio)carbonothioyl)thio)-2-methylpropanoate, bis(4-tert-butyl)benzyl carbonotrithioate, and benzyl (3-((4-(tert-butyl)phenyl)amino)-3-oxopropyl) carbonotrithioate, were synthesized and employed in aqueous RAFT polymerizations. The presented technique allows for the facile preparation of hydrophilic polymers with hydrophobic end groups in aqueous environments. The living/controlled radical polymerization afforded high molecular masses (7500 ≥ Mn ≥ 116 000 g mol-1 for poly(DMAAm), 2500 ≥ Mn ≥ 150 000 g mol-1 for poly(DEAAm), and 4000 ≥ Mn ≥ 50 000 g mol-1 for poly(NIPAAm)) with low PDIs (1.06 ≥ PDI ≥ 1.54 for poly(DMAAm), 1.05 ≥ PDI ≥ 1.39 for poly(DEAAm), and 1.15 ≥ PDI ≥ 1.46 for poly(NIPAAm)). To confirm the living character of the polymerizations, kinetic measurements were undertaken that evidence a linear evolution of molecular weight with conversion. Furthermore, chain extensions were carried out that indicate a very high reinitiation efficiency (poly(DMAAm): from 10 500 to 97 500 g mol-1, PDI = 1.08; poly(DEAAm): from 8500 to 83 000 g mol-1, PDI = 1.13; poly(NIPAAm): from 9000 to 90 000 g mol-1, PDI = 1.11). The resulting polymers were thoroughly characterized via N,N-dimethylacetamide (DMAc) size exclusion chromatography, 1H NMR, and electrospray ionization-mass spectrometry (ESI-MS).
Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
-
Page/Page column 50, (2008/06/13)
Compounds that are antagonists of the VR1 receptor, having formula (I) [image] or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A1, A2, A3, A4, R7, R8, R9, X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.
